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The insulin-like growth factors (IGFs). also known as soma-
tomedins, have been identified as a result of three separate
lines of research carried out over the last 30 years (Van Wyk
& Underwood, 1978). First, IGFs promote incorporation of
35-sulphate into cartilage, hence 'sulphation' factor (Salmon
& Daughaday, 1957). Secondly, they mediate the mitogenic
activity of serum (Pierson & Temin, 1972) and medium
conditioned by rat hepatocytes (multiplication stimulating
activity, MSA; Dulak & Temin. 1973). Thirdy. IGFs have
insulin-like activity which is not inhibited by anti-insulin
antibodies (non-suppressive insulin-like activity, NSILA:
Froesch et al., 1963). Sequence analysis revealed that these
functions are subserved by two main peptide: IGF-I, also
known as somatomedin-C (Klapper et al.. 1983) and IGF-II.
of which the rat form is MSA (Rinderknecht & Humbel.
1978; Marquardt et al.. 1981). The IGF terminology is now
preferred as there is no somatomedin designation for IGF-II
(Daughaday et al.. 1987).
IGF-I (70 residues, MW 7649) and IGF-II (67 residues.
MW 7471) are single chain peptides with around 70%
sequence homology, and 50% homology with pro-insulin.
Mature IGFs have A and B domains where the homology
with proinsulin is highest, a C-peptide domain which has no
sequence homology with proinsulin. and a carboxyterminal
D domain (Daughaday & Rotwein. 1989). The IGF-I gene is
located on chromosome 12q, and the IGF-II gene is on
chromosome llp, contiguous with the insulin gene (Barreca
& Minuto. 1989). In the mouse, the IGF-II gene is imprinted.
that is. there is a difference in expression between the mater-
nal and paternal genes. Specifically, it is the paternal IGF-II
gene which is active (Willison. 1991).
IGF-I is synthesised by the liver and also by other viscera
including kidney and lung (D'Ercole et al., 1984). Hepatic
synthesis, which largely determines serum levels, is regulated
by growth hormone (GH) and also varies with liver function
and nutritional status (Underwood et al., 1986; Zapf &
Froesch. 1986). In endocrine-sensitive tissues. IGF-I gene
expression may be regulated by hormones other than GH.
Notably in rat uterus, IGF-I expression is enhanced by oes-
trogen, and is repressed to a small extent by GH (Murphy &
Friesen, 1988). In vitro, IGF-I is a potent mitogen for normal
cells including chondrocytes and other mesenchymal deriva-
tives (Clemmons & Van Wyk, 1981). In vivo, IGF-I has acute
insulin-like anabolic effects on adipose tissue, muscle and
liver (Zapf & Froesch, 1986; Guler et al.. 1987). However its
most important physiological role is as the primary regulator
of growth, especially of mesenchymal tissues including bone
and cartilage (Schoenle et al., 1982; Van Buul-Offers et al..
1986; Mathews et al., 1988). IGF-II has metabolic and mito-
genic effects experimentally, but its physiological function is
unclear. Serum concentrations are less dependent on GH.
and it causes less growth promotion in hypophysectomised
animals (Schoenle et al., 1983). IGF-II mRNA is expressed in
foetal tissues of mesenchymal origin, including kidney, liver
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and muscle, and also in the CNS (Han et al.. 1987: Brice et
al.. 1989). The suggestion that IGF-lI may be important for
foetal growth is supported by the demonstration of growth
deficiency in foetal mice carrying an IGF-II gene disrupted
by targetting (DeChiara et al., 1990).
IGFs bind to two types of cell surface IGF receptor and
also cross-react with the human insulin receptor (HIR; Rech-
ler & Nissley. 1986). The type I IGF receptor, like the HIR.
is a tetrameric a2 12 complex in which extracellular m (MW
130.000) and transmembrane P (MW 90,000) subunits are
linked by disulphide bonds. The a subunits contain the
ligand binding domains, and the intracellular portion of the P
domain has tyrosine kinase activity (Massague & Czech.
1982). The m and P subunits are generated by cleavage of a
transmembrane precursor polypeptide (Lammers et al.. 1989).
The type I receptor binds IGF-I with high affinity, has 2-3
times lower affinity for IGF-II and 100 times lower affinity
for insulin (Czech, 1989). Sequence analysis of the type I IGF
receptor and HIR shows homology which is most pronoun-
ced (84%) in the tyrosine kinase domains (Ullrich et al..
1986). Both receptors can mediate acute metabolic and
longer-term mitogenic effects. In vitro effects on glucose
transport appear similar. but chimeric receptors possessing
the cytoplasmic domain of the IGF receptor are 10 times
more active in stimulating DNA synthesis and are more
stable (Lammers et al., 1989). It is this receptor which prob-
ably mediates the mitogenic effects of both IGFs and insulin
(Van Wyk et al.. 1985). Other in vivo differences in the
actions of IGF-I and insulin may be attributable to the tissue
distribution of their receptors (Czech, 1989). The type II IGF
receptor is a single chain monomer of MW 250,000. It has
much higher affinity for IGF-II than IGF-I, and negligible
affinity for insulin. Like the IGF-II gene, the murine IGF-II
receptor gene is imprinted, but here it is the maternal gene
which is active (Willison, 1991). The type II receptor is
present on virtually all cell types. and in cultured cells has
been shown to mediate calcium influx and synthesis of DNA
and glycogen (Massague & Czech, 1982). However. it has no
intrinsic kinase activity, and it is not clear what responses are
mediated via this receptor in vivo. Unexpectedly. the human
type II IGF receptor has been found to have 80% and 99%
sequence homology respectively with the bovine and human
mannose-6phosphate receptor (MPR) which participates in
delivery of lysosomal enzymes to the lysosome (Morgan et
al.. 1987; Oshima et al., 1988). Proteins containing mannose-
6-phosphate include lysosomal enzymes such as procathepsin-
D. and pro-TGFP (Rochefort et al., 1987; Czech, 1989). It
now seems that these two distinct functions are indeed sub-
served by the same receptor molecule, suggesting that growth
regulating receptors can interact both with carbohydrates
and growth factors (MacDonald et al., 1988; Roth, 1988).
Circulating IGFs are carried by serum binding proteins
(BPs) which are synthesised mainly in the liver (Froesch &
Zapf, 1985; Hossenlopp et al., 1985; see Table I). Most serum
IGF is carried in a 150,000 MW complex composed of an
acid-labile non-binding a subunit and an acid-stable binding
P subunit known as IGFBP-3 (Baxter, 1988; Czech, 1989). In
this form serum IGFs have a half life of 12-15 h compared
with 10-12 min for the free peptides (Guler et al., 1989). The
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Table I IGF binding proteins
BP Desig-
si-e nation SYnonYms tfajor source Comments
4135 IGFBP3 BP53 Serum Two different 38. 1;egcosv1ated forms
34 IGFBP2 BP31 CSF. serum
30 IGFBP1 BP25 Amniotic fluid. 330o sequence
BP28 serum. homolonv with BP3
Placental HepG2 CM
protein 12
24 IGFBP4 Serum.
fibroblast CM
breast CM
BP = binding protein: CM = conditioned medium. From Hossen-
lopp et al.. 1986: Lamson et al.. 1989.
large complex probablI functions as a serum IGF reservoir.
This is important because unlike other hormones. IGFs are
not stored in cells. but are secreted as soon as thev are
synthesised (Holly & Wass. 1989). A small proportion of
serum IGF is carried on smaller BPs of MW 24-34.000.
Circulating IGF bioactivity is controlled acutely via insulin
which regulates binding protein synthesis in the liver. and
chronicallv via changes in the rate of IGF production (Holly
& Wass. 1989). Small binding proteins are also present in
tissues. and usually inhibit the cellular actions of IGF-I
(Ritvos et al.. 1988: Rutanen et al.. 1988). Mutation or
truncation of the amino terminus of IGF-I generates ana-
logues with reduced affinity for binding proteins and enhanc-
ed biological activity despite reduced serum half-life (Cascieri
et al.. 1988a: Bagley et al.. 1989: Ross et al.. 1989). For
further information on the biochemistn- and function of
IGFs. see reviews by Barreca and Minuto (1989). Daughaday
and Rotwein (1989) and Humbel (1990).
Malignant disease may be associated with inappropriate or
excessive IGF activity. manifest as mitogenic or metabolic
effects.
IGFs as tumour growth factors
IGFs are increasingly recognised as important mitogens in
many tumour types. largely as a result of experimental
studies in titro (Daughadav. 1990). In vivo. tumour cell
growth may be enhanced by IGFs derived from serum or
tumour stroma. In addition. tumour cells with functional
IGF receptors may be able to enhance their own growth bv
synthesis of endogenous IGFs. This process of autocrine
secretion contributes to the partial autonomy and rapid
growth which characterise malignant cells (Sporn & Todaro.
1980). This phenomenon has been studied particularly in the
common solid tumours. including cancers of the lung. breast
and gut. and the results are summarised below.
In addition to their role in promoting growth. it has
recently been suggested that IGFs may play a part in neo-
plastic transformation and metastasis. Over-expression of the
normal human type I IGF receptor in NIH 3T3 cells leads to
ligand-dependent alteration in culture morphology. colony
formation in soft agar and tumorigenicity in nude mice
(Kaleko et al.. 1990). In cultured human melanoma cells, the
type I receptor has been shown to mediate a highly potent
motility response to IGFs and insulin. an effect which could
enhance the potential for local and distant spread (Stracke et
al.. 1989). IGFs and insulin also stimulate motility in human
breast, bladder and ovarian cancer cell lines, and the concen-
trations required for optimal migration appear lower than for
maximal growth stimulation (Kohn et al.. 1990).
Lung cancer
Immunoreactive IGF-I is produced in vitro by human foetal
lung explants and cultured alveolar macrophages (Snyder &
D'Ercole. 1987; Rom et al.. 1988). Dot and Northern blot
analyses show expression of IGF-I and IGF-II throughout
lung organogenesis (Davenport et al.. 1988). IGF-I stimulates
collagen formation by embryonic lung fibroblasts (Goldstein
et al.. 1989) and growth of normal human bronchial epithe-
Hal cells (Seigfried, 1989). Thus IGFs seem to be important
in lung development. and are also implicated in growth
regulation of lung tumours.
Primary lung tumours possess IGF-I binding sites as
shown by autoradiography. with the highest density of recep-
tors in squamous cancers and small cell lung cancer (SCLC:
Shigematsu et al.. 1990). lodinated ligand binding studies on
cultured SCLC cells demonstrate two classes of IGF-I bind-
ing site of high (Kd 0.1-1.1 n.M) and lower (3-4nM) affinity
(Nakanishi et al.. 1988: Macaulay et al.. 1990). These recep-
tors are functional. because exogenous IGF-I causes a mito-
genic response in SCLC cells (Jaques et al.. 1988: Nakanishi
et al.. 1988; Macaulay et al.. 1988a and 1990) and non-SCLC
(Siegfried. 1989). Immunoreactive IGF-I is detectable in
primary lung tumour tissue including non-SCLC (squamous
and adenocarcinoma) and SCLC. at higher levels than in
normal lung (Minuto et al.. 1986: Macaulay et al.. 1988a).
Immunohistochemistrv shows strong staining for IGF-I
especially in cases of squamous lung cancer (Shigimatsu et
al.. 1990). Immunoreactive IGF-I is also detectable in ex-
tracts of cultured SCLC and non-SCLC cells and their condi-
tioned media (Jaques et al.. 1988: Macaulay et al.. 1988a and
1990. Siegfried. 1989). Western blot analysis shows a 16.000
MW band consistent with an incompletely processed IGF-I
precursor (Nakanishi et al.. 1988). However. IGF-I levels are
not raised in the serum of lung cancer patients and levels are
unrelated to bulk of disease or response to treatment. Thus
IGF-I is not a marker for disease activity, presumably reflect-
ing the relatively small contribution of the tumour compared
with hepatic IGF-I production (Macaulay et al.. 1988b).
Indeed circulating IGF-I levels may be low in association
with poor nutritional status or abnormal liver function
(Minuto et al.. 1986). In addition to IGF-I-like peptides, lung
cancer cells can also synthesise IGF BPs. Cross-linking
studies with -'5I-IGF-I or -II show that SCLC conditioned
medium contains IGF BPs with MW of 24-32,000 (Jaques et
al.. 1989). Low MW BPs (25-30.000) are elevated in the
serum of lung cancer patients compared with normal controls
(Reeve et al.. 1990).
Thus there is good evidence that lung cancer cells produce
IGF-I and IGF BPs. express IGF binding sites and exhibit a
mitogenic response to exogenous IGF-I. suggesting that IGF-
I can function as an autocrine growth factor for lung cancer.
Breast cancer
Virtually all cultured breast cancer cell lines and fresh
tumour biopsies express receptors for IGFs I and II and
insulin. -'1I-IGF-I binding studies show a single class of site
with affinity for IGF-I (Kd 0.5-4 nM) which is five times
greater than for IGF-II and 10-100 times greater than for
insulin. IGF-I binding to primary and mestastatic human
breast tumours is increased significantly compared with nor-
mal breast tissue. Cross-linking studies show a 130.000 band.
presumably the alpha subunit of the type I receptor. In low
serum or serum-free medium, growth of cultured breast
cancer cells is stimulated by IGF-I 5 nM. which generates a
greater response than that to optimal concentrations of oes-
tradiol (E2) or epidermal growth factor (EGF). Higher con-
centrations of IGF-II and insulin are required to produce a
similar effect, supporting the suggestion that IGFs and
insulin exert their mitogenic effects via the type I IGF recep-
tor (Furlanetto & DiCarlo, 1984: Pollak et al.. 1988: Peyrat
e- at.. 1988; Foekens et at.. 1989a; Cullen et at. 1990:
Osborne & Arteaga. 1990).
Cultured cells and fresh tumour specimens also express
IGF-I-like activity and levels are 2 10 times higher in oestro-
gen receptor (ER) negative than in ER positive cell lines
(Huff et al.. 1986; Foekens et al., 1989a). Northern analysis
using a cDNA probe to IGF-I reveals a pattern of multiple
cross-hybridising mRNA bands in breast cancer cell lines.IGFs AND CANCER 313
The pattern is more complex than in normal human liver
(Rotwein, 1986), and is very similar to human foetal tissues
(Han et al., 1987), suggesting that breast cancer cells show a
foetal-like IGF mRNA pattern. IGF-II mRNA has also been
detected at low abundance in cultured human breast cancer
cells (Freed & Herington, 1989). Using an antisense RNA
probe which includes the entire coding region of the IGF-IA
precursor in an RNase protection assay, Yee et al. (1989a)
detected expression of IGF-I mRNA in fresh breast cancer
tumour samples. However in situ hybridisation showed that
positivity is confined to stromal cells, with no detectable
IGF-I mRNA in normal or malignant epithelial cells. It is
possible that the neoplastic cells are responsive to IGF-I
secreted by adjacent stroma, suggestng paracrie function
for IGF-I here. Similarly, this group failed to detect authen-
tic IGF-I mRNA in breast cancer cell lines. It was suggested
that the immunoreactive IGF-I detectable in cultured breast
cancer cells and their conditioned media is not therefore
authentic IGF-I from mRNA transcribed from the coding
exons of the IGF-I gene. It could be an IGF-I related
protein, or IGF BP(s) which are known to interfere in IGF-I
radioimmunoassays (Yee et al., 1989a). Radioimmunoassay,
Western ligand blot and Northern analysis show that breast
cancer cell lines produce BPs of MW 24-40,000, compatible
with IGBPs 1, 2 and 3. In ER positive cells, IGFBP mRNA
may be regulated by E2 (DeLeon et al., 1989; Yee et al.,
1989b; Yee et al., 1991).
Regulation of IGF and IGF receptor expression in breast
cancer is further complicated by the fact that cells synthesise
other growth factors including TGFx and P, PDGF and
pro-cathepsin D (52 k protein), and some cell lines and
tumours are hormone sensitive (Osborne & Arteaga, 1990).
Oestradiol-induced growth of breast cancer cells in vitro may
be associated with increased secretion of IGF-I-like peptides
(Huff et al., 1988), but other reports have shown little or no
IGF response to E, (Dickson et al., 1986; Freed & Hering-
ton, 1989). IGF-I synthesis is regulated at a post-transcript-
ional step, and is induced by EGF and TGFa, and inhibited
by TGFPJ, dexamethasone and tamoxifen. Transfection of
hormone-sensitive MCF-7 cells with the v-Harvey-ras onco-
gene leads to increased secretion of immunoreactive IGF-I
and partial autonomy from exongenous IGF-I, oestrogen
and anti-oestrogens (Dickson et al., 1987; Huff et al., 1988).
Breast cancer cell growth and immunoreactive IGF-I secre-
tion are unaffected by growth hormone, basic FGF, PDGF
or prolactin, indicating that IGF-I regulation here occurs by
mechanisms which differ from those in human fibroblasts
(Huff et al., 1988). It is possible that PDGF seceted locally
by breast cancer cells could stimulate synthesis by stromal
fibroblasts ofIGF-I, which in turn could enhance the growth
of the breast cancer cells (Yee et al., 1989a). Further support
for a regulatory link between IGFs and hormones comes
from studies of fresh breast cancer tumour where ER expres-
sion is positively correlated with expression of type I IGF
receptor, and inversely correlated with levels of IGF-I
immunoreactivity (Pekonen et al., 1988; Peyrat et al., 1988;
Foekens et al., 1989a). Unlike ER and EGF receptor expres-
sion, detection of IGF receptor is not of prognostic signifi-
cance (Foekens et al., 1989b). IGF-I can at least partially
substitute for oestrogen in stimulating breast cancer pro-
liferation in vitro and in vivo and may be an important
mediator of oestrogenic effects in breast cancer (Dickson et
al., 1986). However, IGF-I can synergise with E2 in enhanc-
ing progesterone receptor (PR) synthesis by ER positive
MCF-7 cells, suggesting utilisation of different pathways
(Katzenellenbogen & Normon, 1990). IGFs may also be
involved in regulation of cathepsin D synthesis by breast
cancer cells (Cavailles et al., 1989).
Thus there is continuing debate about the role of IGFs as
'oestromedins', given the conflicting evidence regarding the
effect of E2 on endogenous IGF-I-like peptide production,
the doubt as to whether breast cancer cells produce authentic
IGF-I, and the synergy between IGF-I and E2 on PR syn-
thesis (Freed & Herington, 1989; Yee et al., 1989a;Katzenel-
lenbogen & Norman, 1990).
Other solid twnours
IGFs are involved in the normal growth and development of
viscera including the gastrointestinal tract (van Schravendijk
et al., 1987; Laburthe et al., 1988), liver and kidney (D'Ercole
et al., 1984; Fagin & Melmed, 1987). They are also implica-
ted in growth regulation of tumours derived from these
tissues (see Table II). Several studies have demonstrated
over-expression of IGF receptors by tumour cells compared
with the corresponding normal tissues, for example in
thyroid cancer (Yashiro et al., 1989), hepatoma (Hartshorn et
al., 1989) and endometrial carcinoma (Talavera et al., 1990).
Some have shown over-expression of IGFs themselves, for
example the study of Lambert et al. (1990) where IGF-II
mRNA was found to be increased up to 800-fold in colorec-
tal cancers compared with adjacent normal tissues. This
group also detected a restriction fragment length polymorph-
ism in 1/13 cases, suggesting structural modification of one
IGF-II allele in the tumour compared with normal tissue.
Embryonal twnours
Wilms' tumour is thought to arise from embryonal kidney
cells, and most specimens show elevation of IGF-II tran-
scripts to levels comparable with those in foetal kidney
(Reeve et al., 1985; Scott et al., 1985). Although IGF-II
mRNA is over-expressed up to 30-fold, immunoreactive
IGF-II is expressed at only 4-6 times higher levels than
normal kidney. This suggests regulation at the translational
level, the presence of non-functional mRNA, or that IGF-II
is being degraded or secreted more rapidly than normal
(Haselbacher et al., 1987). The IGF-II gene is located on
chromosome llp, near the Wilms' tumour susceptibility gene.
There is a single case report of a Wilms' tumour patient with
a structural alteration in an IGF-II gene, but there is no
other evidence ofIGF-II gene amplification or rearrangement
(Reeve et al., 1985; Irminger et al., 1989). Furthermore, a
study of Wilms' tumour xenografts growing in nude mice
showed inconsistent over-expression of IGF-II mRNA in
successive passage tumours. In this model, therefore, eleva-
tion of IGF-II mRNA does not seem to be an obligatory
event in Wilm's tumour progression (Little et al., 1987).
However the association between the IGF-II gene and
Wilms' tumour has been strengthened by recent genetic
analysis of patients with Beckwith-Wiedemann syndrome
(BWS; Beckwith, 1963; Wiedemann, 1964). This is a rare
foetal over-growth syndrome characterised by exomphalos,
macroglossia, gigantism, hypoglycaemia and visceromegaly.
Around 12% of these patients develop embryonal neoplasia
including Wilms', hepatoblastoma and rhabdomyosarcoma.
Henry et al. (1991) have shown that a significant proportion
of BWS patients have uniparental paternal disomy for
llpl5.5, that is, both copies had been inherited from the
father. The disomic region includes the genes for insulin and
IGF-II. Where loss of an lI pl5.5 allele has occurred in BWS
tumours, it is always the maternal one. If the human IGF-II
gene is imprinted like the murine gene, duplication of the
active paternal allele could explain the features of BWS
(Henry et al., 1991; Little et al., 1991).
IGF-II has also been shown to stimulate the growth of
cells from another embryonal tumour, neuroblastoma. In situ
hybridisation showed that IGF-II mRNA is infrequently
expressed by the tumour cells, but is detectable in all cases in
non-malignant adrenal cortical and stromal cells, suggesting
a paracrmne role for IGF-II here (El-Badry et al., 1991).
IGFs as treatment targets
The evidence reviewed above suggests that IGFs are impor-
tant determinants of tumour growth at least in experimental
models. How far this applies clinically can best be judged by
the extent to which tumour growth is inhibited by blocking
the effects of IGFs. To date there have been only limited
attempts to develop such treatments. This may be partly314 V.M. MACAULAY
Table H Tumour expression of IGFs and IGF receptors
Mitogenic
Production of response to
Tunour IGFs BPs IGF receptors IGFs Comments References
Lung IGF-I 24-32K Type I IGF-I>
IGF-II, insulin
24-40K Type I IGF-I>
Type II insulin IGF-II, insulin
Type I
Type I
Type I receptor expression
correlates with levels of ER.
BP production regulated by
E2
IGF-I production &
IGF-I binding capacity
carcinoma>normal thyroid
IGF-I
Type I + H
Type I +H IGF-I
MSA
Type I
MTC ceUls express IGF-II
mRNA but IGF-II secretion
undetectabk
*IGF BPs not characterised
IGF-I, insulin IGF-II mRNA levels highest
in distal and Duke's C
lesions. IGF-I stimulates
growth of high>low metas-
tatic variant of mouse colon
adenocarcinoma
Jaques et al., 1988, 1989
Macaulay et al., 1988a, 1990
Minuto et al., 1986, 1988
Nakanishi et al., 1988
Reeve et al., 1990
Shigematsu et al., 1990
Siegfried, 1989
Furnaletto & DiCarlo, 1984
Huffet al., 1986, 1988
Peyrat et al., 1988
Pollak et al., 1988
De Leon et al., 1989
Foekens et al., 1989a,b
Freed & Herington, 1989
Yee et al., 1989ahb
Culen et al., 1990
Osborne & Arteaga, 1990
Minuto et al., 1989
Yashiro et al., 1989
Wynne-Williams et al., 1989
Okimura et al., 1989
Suzuki et al., 1989
Verland & Gammeltoft, 1989
Whitehead et al., 1989
Thompson et al., 1990
Tricoli et al., 1986
Pollak et al., 1987
Koenuma et al., 1989
Yee et al., 1989a
Lambert et al., 1990
Hepatoma
Pancreas
Renal
adenocarcinoma
Variable ±
foetal pattern
of IGF-H
mRNA
IGF-I
Endometrial
Neurallneuroendocrine
gina meningoma,
glioma
phaeochromo-
cytoma
Sarcoma
fibro-
lipo-
rhabdo
leiomyo-
Ewings
osteo-
haemangio-
I
25k
BPI
Type I, II and
insulin
Type I
34k Type I
37k, 40k Type I
(BP3)
32k (BP2)
Type I
IGF-II
IGF-I IGF receptors increased in
foetal, regenerating or malig-
nant hepatocytes> normal.
Hepatoma cells retain nor-
mal responses to GH and
insulin
IGF-I
No consistent difference in
BP production or IGF
binding between normal and
malignant tissue
More binding sites on
tumour than normal
endometrium
IGF-I, insulin No IGF-I binding sites on
normal leptomeninges.
Insulin induces
differentiation in cultured
glioma and meningioma cells
IGF-H expression higher
than normal adrenal medulla
IGF-II
IGF-I
Choriocarcinoma IGF-II mRNA
Embryonal car-
cinoma
High MW
IGF-II
IGF-I
Type I
35k Type I, II IGFs, insulin Retinoic acid-induced
differentiation stimulates
synthesis of BP and high
MW IGF-H
Heaton et al., 1986
Cariani et al., 1988
Caro et al., 1988
Lee et al., 1988
Hartshorn et al., 1989
Su et al., 1989
Singh et al., 1990
Ohmura et al., 1990
Pekonen et al., 1989
Lamson et al.. 1989
Talavera et al., 1990
Glick et al., 1989
Kurihara et al., 1989
Haselbacher et al., 1987
Suzuki et al., 1989
De Larco & Todaro, 1978
Hume et al., 1978
Scott et al., 1985
Tricoli et al., 1986
Gloudemans et al., 1990
Blatt et al., 1984
Pavelic et al., 1985
Yee et al., 1989a
Pollak & Richard, 1990
Ritvos et al., 1988
Heath & Shi, 1986
Biddle et al., 1988
Weima et al., 1989
MTC = medullary thyroid carcinoma. GH = growth hormone.
Breast
Thyroid
carcinoma
adenoma
MTC
Thymoma
Gastric
Colon
Authentic
IGF-I produc-
tion by stromal
ceUls not
tumour ceUs
IGF-I
IGF-I
IGF-I
IGF-II
IGF-IIIGFs AND CANCER 315
because of the relatively recent identification of the potential
importance of IGFs in tumour biology, and also because of
recognition that the widespread nature of IGFs and IGF
receptors is likely to pose a problem in terms of treatment
localisation. In general there have been two approaches to
this problem: firstly to block IGF synthesis/secretion, and
hence to reduce local or systemic IGF levels, and secondly to
block the interaction of IGFs with their receptors.
In rats with chemically-induced mammary tumours, chronic
calorie restriction is associated with lowered serum IGF-I
and insulin levels and also with reduction in tumour inci-
dence and multiplicity (Ruggieri et al., 1989). Clinical studies
have used endocrine treatments in an attempt to achieve the
same effect. In normal postmenopausal women and men with
prostate cancer, E2 treatment is associated with a fall in
circulating IGF-I levels. This is presumably a direct inhibi-
tory effect on IGF-I production, given that it is accompanied
by enhancement of growth hormone secretion (Dawson-
Hughes et al., 1986; Stege et al., 1987). In postmenopausal
patients, tamoxifen treatment is associated with a fall in
growth hormone levels, presumably by blocking ERs at the
hypothalamic-pituitary axis (Jordan, 1990). Serum IGF-I
levels are lower in breast cancer patients on tamoxifen than
in control patients of comparable age and status of disease
and nutrition (Colletti et al., 1989; Pollak et al., 1990). It has
been suggested that this could explain the known ability of
tamoxifen to induce remissions in patients whose tumours
are ER negative (Jordan, 1990).
The long-acting somatostatin analogue octreotide (SMS
201-995) has been shown to reduce circulating levels of
various peptides including IGF-I in patients with acromegaly,
carcinoid and other neuroendocrine tumours, and this is
associated in some cases with measurable tumour regression
(Kvols et al., 1986; Lamberts et al., 1987; Schally, 1988).
Pollak et al. (1989) treated eight patients with non-endocrine
solid tumours ofexocrine pancreas, ovary, breast, kidney and
colon. Octreotide therapy was accompanied by a significant
fall in basal and arginine-stimulated growth hormone secre-
tion and in serum IGF-I levels, but no data were given on
tumour response. In 20 patients with SCLC, octreotide treat-
ment was associated with a fall in circulating IGF-I levels in
most patients, but there were no objective clinical responses
(Macaulay et al., 1991). At present it is not clear whether it
will be possible to suppress circulating levels of a potent
mitogen such as IGF-I to the extent that the local tissue
concentration becomes limiting for tumour growth.
There seems more promise in attempts to inhibit the
actions of IGFs by blocking their interaction with the recep-
tor. A monoclonal antibody to IGF-I, SM1.2 (Russell et al.,
1984) has been shown to inhibit the growth of SCLC and
non-SCLC cells in vitro (Minuto et al., 1988; Macaulay et
al., 1990). However, this approach is unlikely to be successful
in vivo, because of the substantial serum reservoir of IGF-I.
In theory a membrane bound target is preferable, because
there is unlikely to be a significant serum reservoir which
would impair the localisation of treatment to the tumour. In
many of the experimental systems described above, the mito-
genic effects of IGFs and insulin appear to be mediated via
the type I IGF receptor, and therefore this has been the
treatment target chosen by most groups. A monoclonal anti-
body to the type I receptor, aIR3 (Kull et al., 1983) has been
shown to inhibit the growth of breast cancer cells in vitro
(Rohlik et al., 1987; Pollak et al., 1988; Freed & Herington,
1989; Arteaga & Osborne, 1989; Cullen et al., 1990). In
serum-supplemented medium aIR3 inhibits the growth of ER
positive and ER negative cell lines. In serum-free defined
medium, aIR3 blocks the mitogenic effects ofexogenous IGF-
I and IGF-H, but does not inhibit basal or Erstimulated
growth (Arteaga& Osborne, 1989; Cullen et al., 1990). This
is consistent with reports that breast cancer cells do not
produce authentic IGF-I (Yee et al., 1989a), and that the
effects of E2 inbreast cancer cells are not mediated solely by IGF-I. In vivo, aIR3 causes dose-dependent inhibition of
tumour take rate and growth of hormone-insensitive breast
cancer xenografts in nude mice, but has no effect on the
hormone-sensitive cell line MCF7 (Arteaga et al., 1989). In
addition, aIR3 has been shown to inhibit the growth in vitro
of human SCLC (Nakanishi et al., 1988; Macaulay et al.,
1990), pancreatic carcinoma (Ohmura et al., 1990) and
neuroblastoma (El-Badry et al., 1989). It also inhibits growth
ofWilms' tumour in vitro and in vivo (Gansler et al., 1989). It
may be that the use of this approach clinically will be con-
founded by the widespread nature of IGF receptors in nor-
mal tissues. However, antibody localisation may be favoured
by the over-expression of IGF receptors by some tumours
compared with the corresponding normal tissues.
There are two further ways of blocking the interaction of
IGFs with receptors. The polyanionic compound suramin has
been shown to inhibit the mitogenic effects of PDGF and
EGF, and has recently been shown to interfere with the
interaction between IGF-I and the type I receptor in cultured
osteosarcoma cells (Pollak & Richard, 1990). This is assoc-
iated with inhibition of IGF-I stimulated proliferation of
these cells in vitro, an effect which is reversed by removal of
the drug, suggesting a cytostatic rather than a cytotoxic
effect. Finally, structure-activity studies indicate that distinct
domains in the IGF-I molecule are responsible for type I
receptor binding and mitogenic activiy (Cascieri et al., 1988b,
Chen et al., 1988). Therefore it might be possible to synthe-
sise an analogue of IGF-I which retains high affinity type I
receptor binding, but which does not activate the receptor,
thus producing an antagonistic effect on growth.
T _mour kypoglycaemis
This rare metabolic manifestation of IGF activity has been
described in patients with mesenchymal tumours including
mesothelioma, fibrosarcoma, rhabdomyosarcoma, leiomyo-
sarcoma, liposarcoma and haemangiopercytoma. It can also
occur in cases of hepatoma, adrenocortical carcinoma, renal
carcinoma, Wilms', and cancers of the breast, prostate and
cervix. The tumours are often large and slow growing and
two thirds are in the abdomen or retroperitoneum, the
remainder being intrathoracic. Patients are characteristically
elderly, and present with symptoms ofhypoglycaemia, especi-
ally confusion, usually preceding the diagnosis ofthe tumour.
Symptoms may be severe, requiring glucose infusion, and
resolve after surgical resection of the tumour (Daughaday,
1989).
For some time it has been recognised that insulin is not the
cause of hypoglycaemia complicating non-islet cell tumours.
Recent molecular studies have confirmed earlier suggestions
that this phenomenon is mediated by IGF production by the
tumour. Northern analysis and RNase protection assay of
three tumours (pleural mesothelioma, thoracic and pelvic
fibrosarcomas) revealed elevated levels of IGF-II mRNA.
There were high circulating levels of immunoreactive IGF-II,
most of which was in a high MW (9,000-15,000) form
(Daughaday et al., 1988; Ron et al., 1989; Daughaday, 1990).
Other studies have confirmed over-expression of IGF-II
mRNA, without IGF-H gene amplification or rearrangement
(Lowe et al., 1989). It is suggested that IGF-II causes hypo-
glycaemia by stimulating glucose uptake into peripheral tis-
sues (fat and muscle) and possibly also into the tumour. In
addition, a negative feed-back effect on growth hormone
secretion impairs the hepatic response to hypoglycaemia, and
suppresses serum IGF-I levels (Axelrod & Ron, 1988). How-
ever, several groups have been unable to show any elevation
of circulating IGF-II in patients with tumour hypoglycaemia
(Widmer et al., 1983; Merimee, 1986). One patient with a
para-ovanan sarcoma, hypoglycaemia and high tumour IGF-
II mRNA had suppressed serum IGF-I and IGF-II, presum-
ably as a consequence of the hypoglycaemia, and neither the
tumour cyst fluid nor the primary tissue culture conditioned
medium had high IGF-II levels (Schofield et al., 1989). This
over-expression of mRNA without apparent increase in pep-
tide production is analogous to the situation described in
Wilms' (Haselbacher et al., 1987).316 V.M. MACAULAY
Two aspects of IGF biology may explain the apparent lack
of correlation between the degree of hypoglycaemia and
measured levels of circulating IGF-II. Firstly, several studies
have demonstrated the presence of high MW incompletely
processed pro-IGF-II in tumours and sera of hypoglycaemic
patients with hepatoma and fibrosarcoma but not in eugly-
caemic patients with hepatoma (Daughaday et al.. 1988 and
1990; Shapiro et al., 1990). This 'big IGF-II is fully reactive
with the IGF-II receptor (Daughaday et al.. 1988) but has
lower affinity for serum IGF BPs than authentic IGF-II
(Shapiro et al., 1990). Secondly. the 150.000 MW IGF BP
complex appears to be absent from the serum of some
patients with tumour hypoglycaemia, replaced in some cases
with 110.000 and 60.000 MW complexes (Daughaday &
Kapachia. 1989). Thus it is possible that a greater proportion
of circulating IGF-II is unbound, or that the reduction in
IGF-II,BP binding affinity is sufficient to alter the equili-
brium in favour of IGF-II binding to cell surface receptors.
Also. the IGF-II in lower MW complexes may penetrate
better into tissues. again facilitating interaction with the
receptor. These factors may explain the severe symptoms of
hypoglycaemia which can occur in the presence of modest no
elevation in absolute levels of serum IGF-II.
Conclusions
This review has covered the two main manifestations of
inappropriate or excessive IGF activity in cancer. Tumour
hypoglycaemia is a rare paraneoplastic manifestation of the
metabolic effects of IGFs. Of potentially greater importance
is the role of IGFs as tumour growth factors. IGF-I has been
implicated in growth regulation of a variety of neoplasia
especially the common solid tumours, and IGF-II in embry-
onal tumours. This parallels the importance of IGF-I in
normal post-natal growth, and the suggestion that IGF-II is
an important regulator of foetal development. Notably. ex-
clusive paternal expression of IGF-II has been linked with a
foetal overgrowth syndrome. BWS. and with the embryonal
tumours associated with it. Recent studies have questioned
whether tumours are capable of synthesising authentic IGF-I.
but there is little doubt that many neoplastic cells express
IGF receptors and show growth enhancement in response to
IGFs derived from serum or released locally by stromal cells.
Although the same is true of many normal tissues, the in-
creased IGF binding capacity of tumour tissue compared
with its normal counterpart may favour localisation to the
tumour of any IGF-directed treatment. The value of this
approach is currently being tested experimentally. but has yet
to be evaluated clinically.
I am grateful to Professor Judson Van Wyk and Dr Jeff Holly for
their advice. and to Mrs Julia Holborn for typing the manuscript.
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